Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

    Recruiting

    3 1 1
    Germany Greece Italy Poland Portugal Romania +1
  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Denmark France Italy Spain
  • Study on AZD0901 and Drug Combination for Patients with Advanced Gastric, Gastroesophageal, and Pancreatic Cancers Expressing Claudin 18.2

    Recruiting

    1 1 1 1
    Poland Spain
  • Study of Avelumab with Chemotherapy for Patients with Resectable Stomach or Gastroesophageal Junction Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Spain
  • Study of BOLD-100 with FOLFOX chemotherapy (fluorouracil, folinic acid, and oxaliplatin) in patients with advanced gastrointestinal tumors, colorectal, gastric, or pancreatic cancer

    Recruiting

    2 1 1 1
    Germany Ireland Italy Spain
  • Study on Pre-operative Capecitabine, Oxaliplatin, Docetaxel, and Atezolizumab for Patients with Resectable Gastric or Gastro-esophageal Junction Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    The Netherlands
  • Study Comparing Survival in Patients with Advanced or Metastatic Gastric Cancer Treated with Botensilimab and Balstilimab vs. Standard Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    France
  • Study of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer

    Recruiting

    2 1 1 1
    France
  • Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

    Recruiting

    2 1 1 1
    Spain Sweden
  • Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Italy